(Ranked by impact factor of the journal)|
TRIM38 Inhibits TNFα- and IL-1β-Triggered NF-κB Activation by Mediating Lysosome-Dependent Degradation of TAB2/3|
Investigators identified tripartite-motif protein 38 (TRIM38) as a critical negative regulator of TNFα- and IL-1β-triggered signaling. Overexpression of TRIM38 inhibited activation of NF-κB and induction of downstream cytokines following TNFα and IL-1β stimulation, whereas knockdown or knockout of TRIM38 had the opposite effects. [Proc Natl Acad Sci USA]
Alarmin IL-33 Acts as an Immunoadjuvant to Enhance Antigen-Specific Tumor Immunity
Two biologically active isoforms of IL-33 exist that are full-length or mature, but the ability of either isoform to function as a vaccine adjuvant that influences CD4 Th1 or CD8 T cell immune responses is not defined. Researchers showed that both IL-33 isoforms are capable of enhancing potent antigen-specific effector and memory T cell immunity in vivo in a DNA vaccine setting. [Cancer Res]
Abstract | Press Release
IL-17-Producing NKT Cells Depend Exclusively on IL-7 for Homeostasis and Survival
Scientists showed that natural killer T (NKT)17 cells deviate from other NKT cells in their survival requirements. In contrast to conventional NKT cells that are maintained by IL-15, RORγt+ NKT cells are IL-15 independent and instead rely completely on IL-7. [Mucosal Immunol]
Conventional CD4+ T Cells Regulate IL-22-Producing Intestinal Innate Lymphoid Cells
The authors found that CD4+ T cells regulate the number and function of barrier-protective innate lymphoid cells (ILCs), as well as production of antimicrobial peptides (AMPs), Reg3γ and Reg3β. RAG1−/− mice lacking T and B cells had elevated ILC numbers, interleukin-22 (IL-22) production, and AMP expression, which were corrected by replacement of CD4+ T cells. [Mucosal Immunol]
Excess IL-1 Signaling Enhances the Development of Th17 Cells by Downregulating TGF-β-Induced Foxp3 Expression
The authors found that IL-21 production was increased in the lymph nodes of IL-1R antagonist-deficient (Il1rn−/−) mice, naive Il6−/− CD4+ T cells differentiated into Th17 cells when cultured with TGF-β and IL-21, and the differentiation was greatly enhanced when IL-1 was added to the culture. [J Immunol]
IL-21 Contributes to Fatal Inflammatory Disease in the Absence of Foxp3+ T Regulatory Cells
To distinguish the effect of IL-21 on the immune system from that of its effect on T regulatory cells (Tregs), investigators analyzed the role of IL-21/IL-21R signaling in mice made genetically deficient in IL-2, which exhibit a deficit in IL-2-dependent Foxp3 Tregs and suffer from a fatal multiorgan inflammatory disease. [J Immunol]
A Requirement of Dendritic Cell-Derived Interleukin-27 for the Tumor Infiltration of Regulatory T Cells
Scientists demonstrated that in the absence of dendritic cell-derived interkeukin (IL)-27, regulatory T cells (Foxp3+CD4+) were decreased significantly in transplanted B16 melanoma, transplanted EL-4 lymphoma, and MCA-induced fibrosarcoma by using IL-27p28 conditional KO mice. [J Leukoc Biol]
to our sister publications: Human Immunology News
and Immunology of Infectious Disease News!|
ITN Wins NIH Award for Collaborative Network for Tolerance Research|
The National Institute of Allergy and Infectious Disease announced that the Immune Tolerance Network (ITN) has been awarded a UM1 grant for a Collaborative Network for Clinical Research on Immune Tolerance. The current grant will allow the ITN to continue to develop, fund and implement mechanistically-focused clinical trials for novel therapies in transplantation, allergy and autoimmune diseases. [Immune Tolerance Network]
MD Anderson Announces Collaboration with Johnson & Johnson Innovation on Cancer Immunotherapy
The University of Texas MD Anderson Cancer Center will collaborate with Johnson & Johnson Innovation, LLC, and its affiliate Janssen Biotech, Inc., to develop immunology-based cancer treatments through the MD Anderson Moon Shots Program immunotherapy platform. [The University of Texas MD Anderson Cancer Center]
Biocon Collaborates with Advaxis for ‘ADXS-HPV’ A Novel Cancer Immunotherapy
Biocon Ltd. and Advaxis, Inc. announced that they have entered into an exclusive licensing agreement for co-development and commercialization of ADXS-HPV, a novel cancer immunotherapy for the treatment of human papillomavirus (HPV)-associated cervical cancer in women, for India and key emerging markets.
The HUB Foundation for Organoid Technology and STEMCELL Technologies Sign Agreement on the Manufacturing of Cell Culture Media for Organoids
The HUB Foundation for Organoid Technology announced that it has signed a licensing agreement with STEMCELL Technologies Inc. for the manufacturing and worldwide distribution of cell culture media for growing Organoids. Organoids are mini-organs grown in tissue culture from small pieces of tissue derived from patients with cancer and other diseases, and represent an exciting new tool for scientific research and drug discovery and validation. [STEMCELL Technologies Inc.]
From our sponsor:
View immunology lectures, protocols and other resources on the Human Immunology Portal.
we missed an important article or publication in Immune Regulation News? Click here to submit!
Comments or Suggestions? Submit your feedback here.